Mechanism of action for ZERBAXA\u00ae (ceftolozane and tazobactam)<\/strong><\/h1><\/div>\n\n\n\nZERBAXA combines a novel cephalosporin that has bactericidal action with a proven beta-lactamase inhibitor<\/strong><\/h2><\/div>\n\n\n\nLearn about:<\/strong><\/h2><\/div>\n\n\n\n\n- Mechanism of action<\/a><\/em><\/li>
- Antimicrobial activity<\/a><\/em><\/li>
- Mechanisms of resistance<\/a><\/em><\/li><\/ul><\/div>\n\n\n\n\n<\/div>\n\n\n\n
Mechanism of action<\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n\n\n\n![\"Ceftolozane](\"https:\/\/www.merckconnect.com\/zerbaxa\/wp-content\/uploads\/sites\/130\/2025\/10\/CAT_Ceftolozane_Tazobactam_dk_Rb.svg\")
<\/figure><\/div>\n<\/div>\n\n\n\n<\/div>\n<\/div>\n\n\n\n<\/div>\n\n\n\nAntimicrobial activity<\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\nZERBAXA has been shown to be active against the following bacteria, both in vitro and in clinical infections.<\/p>\n\n\n\n
<\/div>\n\n\n\nHospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP\/VABP)<\/h3><\/div>\n\n\n\n\n\nGram-negative bacteria<\/strong><\/h2><\/div>\n\n\n\n\n\n
ZERBAXA combines a novel cephalosporin that has bactericidal action with a proven beta-lactamase inhibitor<\/strong><\/h2><\/div>\n\n\n\nLearn about:<\/strong><\/h2><\/div>\n\n\n\n\n- Mechanism of action<\/a><\/em><\/li>
- Antimicrobial activity<\/a><\/em><\/li>
- Mechanisms of resistance<\/a><\/em><\/li><\/ul><\/div>\n\n\n\n\n<\/div>\n\n\n\n
Mechanism of action<\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n\n\n\n<\/figure><\/div>\n<\/div>\n\n\n\n<\/div>\n<\/div>\n\n\n\n<\/div>\n\n\n\nAntimicrobial activity<\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\nZERBAXA has been shown to be active against the following bacteria, both in vitro and in clinical infections.<\/p>\n\n\n\n
<\/div>\n\n\n\nHospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP\/VABP)<\/h3><\/div>\n\n\n\n\n\nGram-negative bacteria<\/strong><\/h2><\/div>\n\n\n\n\n\n
Learn about:<\/strong><\/h2><\/div>\n\n\n\n\n- Mechanism of action<\/a><\/em><\/li>
- Antimicrobial activity<\/a><\/em><\/li>
- Mechanisms of resistance<\/a><\/em><\/li><\/ul><\/div>\n\n\n\n\n<\/div>\n\n\n\n
Mechanism of action<\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n\n\n\n<\/figure><\/div>\n<\/div>\n\n\n\n<\/div>\n<\/div>\n\n\n\n<\/div>\n\n\n\nAntimicrobial activity<\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\nZERBAXA has been shown to be active against the following bacteria, both in vitro and in clinical infections.<\/p>\n\n\n\n
<\/div>\n\n\n\nHospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP\/VABP)<\/h3><\/div>\n\n\n\n\n\nGram-negative bacteria<\/strong><\/h2><\/div>\n\n\n\n\n\n
- Mechanism of action<\/a><\/em><\/li>
- Antimicrobial activity<\/a><\/em><\/li>
- Mechanisms of resistance<\/a><\/em><\/li><\/ul><\/div>\n\n\n\n\n
<\/div>\n\n\n\nMechanism of action<\/strong><\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\n\n\n\n<\/figure><\/div>\n<\/div>\n\n\n\n<\/div>\n<\/div>\n\n\n\n<\/div>\n\n\n\nAntimicrobial activity<\/strong><\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\nZERBAXA has been shown to be active against the following bacteria, both in vitro and in clinical infections.<\/p>\n\n\n\n
<\/div>\n\n\n\nHospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP\/VABP)<\/h3><\/div>\n\n\n\n
\n\nGram-negative bacteria<\/strong><\/h2><\/div>\n\n\n\n\n\n
- Antimicrobial activity<\/a><\/em><\/li>